This is the authors' abstract. We don't add key points for this paper.
OBJECTIVES: To determine the effectiveness of a single perioperative prophylactic 2 g dose of cephalexin in preventing surgical site infection (SSI) following excision of skin lesions from the lower limb. DESIGN: Prospective double-blinded placebo-controlled trial testing for difference in infection rates. SETTING: Primary care in regional North Queensland, Australia. PARTICIPANTS: 52 patients undergoing lower limb skin lesion excision. INTERVENTIONS: 2 g dose of cephalexin 30-60 min before excision. MAIN OUTCOME MEASURES: Incidence of SSI. RESULTS: Incidence of SSI was 12.5% (95% CI 2.7% to 32.4%) in the cephalexin group compared with 35.7% (95% CI 18.6% to 55.9%) in the placebo group (p=0.064). This represented an absolute reduction of 23.21% (95% CI -0.39% to 46.82%), relative reduction of 65.00% (95% CI -12.70% to 89.13%) and number-needed-to-treat of 4.3. CONCLUSIONS: Administration of a single 2 g dose of cephalexin 30-60 min before skin lesion excision from the lower limb may produce a reduction in the incidence of infection; however, this study was underpowered to statistically determine this. TRIAL REGISTRATION NUMBER: ACTRN12611000595910.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Smith et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: